Duke, Mattyedw answered your question fairly and what's a normal discussion anyway in today's polarized and misinformation riddled environs.
Please listed to our CEO for some more clues that may help you establish whether it's reasonable or not to believe that a preclinical - before Phase 1 starts in the 2H of this year - licencing deal for one or both of PAB's agents is most probable:
@9.40 and @11.50 marks in the video
I know what you're saying and that's also why I'd stress that:
NOT FINANCIAL ADVICE, DYOR
Ann: Appendix 4C - Quarterly - 31 December 2022, page-19
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
-0.001(12.5%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $21.39K | 3.056M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 6182265 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 2976726 | 5 |
View Market Depth
| Last trade - 15.57pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.7¢ |
Change
-0.001 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 0.8¢ | 0.8¢ | 0.7¢ | 2373466 | ||
| Last updated 15.35pm 16/05/2024 ? | |||||
| PAB (ASX) Chart |